FDA Approves Alzheimer’s Drug Lecanemab Amid Safety Concerns
The US Food and Drug Administration (FDA) has approved lecanemab, the second-ever treatment for Alzheimer’s disease intended to tackle the root of the condition and slow cognitive decline. Researchers welcome the decision, but the excitement is clouded by patient deaths and reports that the FDA acted improperly when approving the first such drug last year. By […]
